These highlights do not include all the information needed to use LOKELMA® safely and effectively. See full prescribing information for LOKELMA®. LOKELMA® (sodium zirconium cyclosilicate) for oral suspension Initial U.S. Approval: 2018
Lokelma for treating hyperkalaemia in China – Future Medicine India
Dosing and Administration for Dialysis and Non-Dialysis Patients | LOKELMA® (sodium zirconium cyclosilicate) 5g | 10g for oral suspension | For HCPs
Pharmacy Practice News Clinical JUNE 10, 2021 Potassium-Sparing Agents Put a Rise in RAASis By Gina Shaw Newer agents are reenergizing the treatment of hyperkalemia, a serious condition characterized by elevated serum potassium levels in patients ...
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia | American Society of Nephrology
Another small step forward for Lokelma with UK reimbursement easing
Lokelma (Sodium Zirconium Cyclosilicate): Uses, Dosage, Side Effects, Interactions, Warning
Lokelma sodium zirconium cyclosilicate treatment for hyperkalaemia
Hyperkalemia Treatment Lokelma Gets FDA Approval - MPR
A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study of Sodium Zirconium Cyclosilicate for Reducing the Incidence of Predialysis Hyperkalemia | American Society of Nephrology
JCM | Free Full-Text | Optimization of RAASi Therapy with New Potassium Binders for Patients with Heart Failure and Hyperkalemia: Rapid Review and Meta-Analysis | HTML
FDA Approves a Label Update for Lokelma to Include Dosing Guidance for Treatment of Hyperkalemia in ESRD on Hemodialysis | Specialty Pharma Journal
Clinical Management of Hyperkalemia - Mayo Clinic Proceedings
Lokelma Full Prescribing Information, Dosage & Side Effects | MIMS Singapore
PDF) The LIFT trial: study protocol for a double-blind, randomised, placebo-controlled trial of K-binder Lokelma for maximisation of RAAS inhibition in CKD patients with heart failure
Drug Trials Snapshots: LOKELMA | FDA
Drug Trials Snapshots: LOKELMA | FDA
Mechanism of Action | LOKELMA® (sodium zirconium cyclosilicate) 5g | 10g for oral suspension | For HCPs